HERCULES, Calif., July 31, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based ...

HERCULES, Calif. - Bio-Rad Laboratories (NYSE:BIO), Inc. (NYSE: BIO and BIO.B), a $8.49 billion market cap company known for its life science research and clinical diagnostics products, has announced ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James ...

HERCULES, Calif., July 07, 2025--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today announced that MicroVal, the international certification organization for the validation ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, today announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ...

Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net ...

Normal Schwartz has been the Chief Executive Officer or CEO, President, and Chairman of Bio-Rad laboratories since 2003. Meet Bio-Rad laboratories chief executive officer or CEO, Norman Schwartz. The ...

BIO is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of BIO shares has decreased $1.52 since the market last closed. This is a 0.50% ...